查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2005192

間質幹細胞/治療訊號細胞（MSCs）：進展與應用（2026）

Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) - Advances & Applications, 2026
出版日期: | 出版商: BioInformant | 英文 381 Pages | 訂單完成後即時交付

價格
簡介目錄

執行摘要

間質幹細胞（MSCs）是多功能細胞，也被稱為間質幹細胞、治療性訊號細胞或間質支持細胞，這反映了它們的多功能性和廣泛的應用。 MSCs可以分化成多種細胞類型，包括成骨細胞、軟骨細胞、肌肉細胞和脂肪細胞。由於其獨特的分泌促進組織修復因子以及透過抗發炎和抗纖維化作用調節微環境的能力，MSCs在再生醫學中不可或缺。此外，其免疫逃脫特性使MSCs特別適用於同種異體移植。

間質幹細胞是眾多產業的重要原料，包括再生醫學、藥用化妝品和培養肉生產。主要應用領域包括：

  • 細胞療法用於治療肌肉骨骼疾病、脊髓損傷和心血管疾病。
  • 人造組織和器官，如皮膚、骨骼、血管和肝臟。
  • 細胞衍生產品，如外泌體和生長因子，被用於化妝品和護膚品中。
  • MSCs在肌肉發育和培養肉生產中的作用，利用其分化成肌肉細胞和脂肪細胞的能力。

在全球範圍內，已有 12 種使用間質幹細胞 (MSC)的治療方法核准用於各種適應症，其中大部分集中在韓國、日本和歐盟。

具體而言，韓國已核准五種產品上市：Anterogen公司的「Queencell」、Pharmicell公司的「Cellgram AMI」和「Cupistem」、Medipost公司的「Cartistem」以及Corestem公司的「NeuroNata®」。日本已核准兩種產品上市：JCR Pharmaceuticals公司的「​​Temcell HS」和Nipro Corporation公司的「Stemirac」。歐洲藥品管理局（EMA）已核准兩種產品上市：Chiesi Farmaceutici公司的「Holoclar」和TiGenix/Takeda公司的「Alofisel」。印度已批准產品上市：Stempeutics公司的「​​Stempeucel」。伊朗已批准一種產品核可產品核可：Cell Tech Pharmae​​d公司開發的「MesestroCell」。最後，澳洲已產品核可：Mesoblast公司的「Remestemcel-L」。

儘管取得了這些進展，但目前還沒有任何基於 MSC（間質幹細胞）的療法獲得美國 FDA 的核准，儘管 FDA 正在積極審查 Mesoblast 的「Remestemcel-L」。

在藥用化妝品市場，間質幹細胞（MSC）衍生產品，尤其是外泌體，因其抗衰老齡化和再生特性而迅速走紅，歐萊雅和強生等公司已在該領域投入巨資。同樣，培養肉公司也利用MSC生產肌肉和脂肪細胞，以改善口感和質地。 Upside Foods和Good Meat等公司的人造雞肉等突破性核准，為該行業的進一步發展鋪平了道路。

利用間質幹細胞的基因編輯技術也不斷發展，使得過度表現抗腫瘤基因和治療因子成為可能。研究人員也正在探索將間質幹細胞應用於3D列印和人工器官製造，預計未來十年將取得突破性進展。

值得注意的是，像Cynata Therapeutics這樣的公司率先開發了iPS細胞衍生的間質幹細胞（MSC）生產技術，從而實現了大規模的治療藥物開發。目前，至少有八家公司參與了iPS細胞衍生的MSC（iMSC）療法的研發，其中包括Cynata Therapeutics、Eterna Therapeutics、Implant Therapeutics、Bone Therapeutics、Brooklyn ImmunoTherapeutics、Fueum CDI、Citius Pharmaceuticals和Kiji Therapeutics。

此外，ClinicalTrials.gov網站列出了超過1,670項涉及間質幹細胞（MSCs）的臨床試驗。其中約75%（四分之三）的臨床研究將MSCs用於再生醫學（RM）產品的開發。約14%的研究將MSCs用於疾病建模。其餘11%的研究將MSCs用於藥物發現和細胞毒性測試。

這些試驗面臨的挑戰包括在生長過程中維持間質幹細胞的表現型和功能。然而，由於持續的進展，未來前景光明，預計到2040年，全球至少將有50種基於間質幹細胞的產品核准，平均每年新核准。

MSC研究產品領域的主要企業

近年來，對使用間質幹細胞（MSCs）的研究產品的需求激增，促使領先的供應商擴展其產品線。像RoosterBio這樣的公司正在透過工業化的供應鏈、標準化的細胞庫產品形式以及符合cGMP規範的專用細胞和培養基系統，擴大高品質MSCs的取得途徑。

其他主要的 MSC 研究產品供應商包括 PromoCell、Lonza、Thermo Fisher Scientific、STEMCELL Technologies、Miltenyi Biotec、Bio-Techne (R&D Systems)、ScienCell Laboratory 和 ATCC。

挑戰與機遇

儘管間質幹細胞的商業化面臨規模化生產和監管核准等諸多挑戰，但也蘊藏著許多機會。基於間質幹細胞的產品市場預計將在科研、治療、化妝品和食品等行業中顯著成長。

在這個瞬息萬變的環境中，充分了解你的競爭對手至關重要。

這份全球策略報告介紹了與間質幹細胞（MSCs）相關的臨床試驗數據、科學出版物、專利、資金籌措案例和合作趨勢。報告還重點展示了基於MSCs的治療產品線，分析了市場機會和挑戰，並探討了未來的發展方向和新興應用領域。此外，報告還著重介紹了125家領先競爭對手提供的創新MSC產品、服務和技術。最後，該報告提供了全球MSC市場的詳細市場規模數據，並按地區和業務部門進行了細分，同時對2031年之前的市場進行了預測。

目錄

第1章：報告概述

  • 報告內容
  • 目標受眾
  • 本報告的資訊來源
  • 報告目標
    • 研究領域的最新進展
    • 概述全球MSC市場。
    • 獲得商業化機會
    • 確定主要市場參與企業並評估競爭格局。
    • 識別現有趨勢和新趨勢
    • 識別MSC市場中的關鍵機會與威脅。
  • 執行摘要
  • 介紹

第2章間質幹細胞（MSCs）：概述

  • 人類間質幹細胞（hMSCs）穩定化技術
  • 間質幹細胞對再生醫學的影響
  • MSC命名法時間表
  • MSC的供應來源
    • 骨髓間質間質幹細胞（BM-MSCs）
    • 脂肪來源間質間質幹細胞（AD-MSCs）
    • 臍帶間間質幹細胞（UC-MSCs）
    • iPSC衍生的間質幹細胞（iMSCs）
  • 間間質幹細胞的細胞表面標誌物
  • 間質幹細胞的體外分化潛能
  • 間質幹細胞分泌的可溶性因子
  • 間質幹細胞
  • 間質幹細胞的類型及其生物醫學應用
  • 對間質幹細胞特性至關重要的基因

第3章：間質幹細胞臨床試驗的現狀

  • 利用間質幹細胞進行區域臨床研究
  • 目前臨床試驗中使用的間質幹細胞來源
  • 自體和異體間質幹細胞在臨床試驗中的佔比
  • 基於MSC的臨床試驗依疾病適應症分類。
  • 基於MSC的臨床試驗（依研究階段分類）
  • 選擇一項使​​用MSC的臨床試驗
    • 利用間質幹細胞治療肌肉骨骼疾病的臨床試驗
    • 利用間質幹細胞治療神經系統疾病的臨床試驗
    • 利用間質幹細胞來源外泌體的臨床試驗
    • 臨床試驗中的預處理間質幹細胞
    • 利用支架型間質幹細胞的臨床試驗

第4章 間間質幹細胞（MSCS）：專利趨勢

  • MSC專利公開資訊（依管轄區分類）
  • MSC專利申請人
  • MSC專利發明人
  • MSC專利持有人
  • MSC專利申請的法律地位
  • 與MSC衍生外泌體相關的專利
  • 與iPSC衍生MSC（iMSC）相關的專利
  • MSC專利按治療類型分類

第5章：已發表的MSCS科學論文

  • PubMed.gov 上發表的關於 MSC 在細胞治療中應用的文章
  • 一篇發表在PubMed.gov上的關於基於MSC的免疫療法的論文
  • 一篇關於間質幹細胞在基因治療應用的論文發表在PubMed.gov網站上。
  • 一篇關於間質幹細胞在組織工程中應用的論文發表在PubMed.gov網站上。
  • PubMed.gov 上發表的關於 MSCs 在美容醫學中應用的文章
  • 關於間質幹細胞在主要疾病中應用的已發表論文數量
  • 關於改進型MSC的出版品
  • 已發表的關於MSC衍生外泌體的論文

第6章：MSC製造平台：概述

  • 分離間質幹細胞的方法
  • 細胞增殖：從傳統培養到生物反應器
    • 單層培養系統
    • 利用生物反應器進行細胞增殖
    • 目前正在使用的生物反應器
    • MSC擴展系統：概述
    • 以技術計算的每批次細胞計數
    • 用於細胞增生的微載體
  • MSC的下游工藝
    • 細胞脫離和分離（收穫）
    • 細胞洗滌和濃縮
    • 安全性和有效性測試
    • 區分間質幹細胞和纖維母細胞的表面標誌物
  • 自製均質MSC生產：比較
    • 同種異體間質幹細胞的生產成本
    • 內部生產MSC的成本
    • 捐贈者篩檢和檢測的費用
    • 發布測試成本
  • MSC的大規模生產
    • MSC製造平台
    • 擴大細胞培養容器的規模
    • 培養基
    • 間質幹細胞的冷凍保存

第7章 細胞和基因療法的契約製造

  • 人員短缺
  • 對自動化的需求
  • 容量限制
  • 一個潛力較大的CDMO平台
  • CMO/CDMO
    • 受託製造廠商（CMO）
    • 受託製造廠商（CDMO）
  • 製造設施的地理分佈
  • 外包業務的持續成長
  • 美國主要CDMO（藥品契約製造開發組織）
  • 歐洲領先的細胞和基因治療CDMO
  • 英國在歐洲契約製造領域的統治地位

第8章：提升間質幹細胞功能的生物工程解決方案

  • 間間質幹細胞的低分子量預處理
  • MSC粒子工程
  • MSC基因工程
  • 利用生物工程改造的間質幹細胞生產抗癌藥物的實例
  • 用於治療神經系統疾病的基因修飾間質幹細胞
  • 基因工程改造的間質幹細胞用於治療心血管疾病
  • 間質幹細胞治療肺損傷
  • 基因改造的間質幹細胞用於治療糖尿病
  • 利用生物工程方法改善間質幹細胞給藥

第9章：MSCS 針對的主要疾病

  • 利用間質幹細胞治療自體免疫疾病的研究
  • 利用間質幹細胞治療心血管疾病的研究
  • 利用間質幹細胞治療神經退化性疾病的研究
  • 利用間質幹細胞治療骨骼和軟骨疾病的研究
  • 利用間質幹細胞治療移植物抗宿主疾病的研究
  • 利用間質幹細胞治療克隆氏症的研究
  • 利用間質幹細胞治療第1型糖尿病的研究
  • 利用間質幹細胞（MSCs）治療全身性紅斑性狼瘡（SLE）的研究
  • 利用間質幹細胞治療帕金森氏症的研究
  • 利用間質幹細胞治療阿茲海默症的研究
  • 利用間質幹細胞治療腎衰竭的研究
  • 利用間質幹細胞治療脊髓損傷的研究
  • 利用間質幹細胞進行創傷治療的研究

第10章：MSC領域近期合作（2020-2024）

  • BioSolution Designs 與 RoosterBio 建立合作關係
  • CytoMed Therapeutics有限公司與盛港綜合醫院建立合作關係
  • REPROCELL 與 Histocell 的合作關係
  • 富士軟片Diosynth與RoosterBio建立合作關係
  • RoosterBio與AGC Biologics的合作
  • RoosterBio與ShiftBio的合作
  • RoosterBio與Univercells Technologies的合作
  • Cynata與富士軟片的合作關係
  • 美國 CryoStem 公司與 BioTherapeutic Lab 公司建立合作關係
  • RoosterBio與Sartorius的合作關係
  • 美國冷凍幹細胞公司與合作研發協議
  • RoosterBio與Sartorius Korea Biotech達成合作
  • Catalent與BrainStorm的合作關係
  • 西普拉和史泰普蒂克斯的合作關係
  • Aethlon與匹茲堡大學的合作
  • RoosterBio與Senti Biosciences的合作

第11章：全球市場中的MSC基產品

  • 核准幹細胞療法
    • 女王牢房
    • Cellgram AMI
    • 庫皮斯特姆
    • 邪教
    • NeuroNataR
    • 全像
    • 原始基材/ Lionsil (Remestemcell-L)
    • 坦塞爾高中
    • 斯滕·皮尤塞爾
    • MesestroCell
    • 斯替米拉克
    • Royboshen（Amimestrocell）
  • 市售生物材料基間質幹細胞及間質幹細胞前驅細胞
    • Osteocel
    • AlloStem
    • Grafix
    • Cellentra VCBM
    • Trinity ELITE
    • Map3
    • BIO4
    • Trinity Evolution
    • Carticel
    • Chondron
    • DeNovo NT
    • Ossron
    • JACC
    • MACI
    • Ortho-ACI
    • Ossgrow
    • Cartigrow
  • 含有間質幹細胞/間質幹細胞衍生外泌體的局部用化妝品

第12章 市場分析

  • MSC療法的市場規模
  • 全球對間質幹細胞（MSCs）的需求

第13章：公司簡介

  • Advancells
  • Aegle Therapeutics
  • AGC Biologics
  • AlloSource, Inc.
  • Ambulero
  • American CryoStem Corporation
  • American Type Culture Collection (ATCC)
  • Amniotics
  • Andelyn Biosciences
  • Anemocyte Srl
  • Anterogen, Co., Ltd.
  • Avid Bioservices, Inc.
  • Bacthera
  • Baylx, Inc.
  • BioCardia
  • BioCentriq
  • BioEden, Inc.
  • Bioinova sro
  • BioRestorative Therapies
  • Bioscience Institute SpA
  • Blue Horizon International, LLC
  • Boehringer Ingelheim BioXellence
  • Bonus Biogroup, Ltd.
  • BrainStorm Cell Therapeutics, Inc.
  • Catalent
  • CCRM
  • Cell2Cure ApS
  • Cell Care Therapeutics
  • Cellcolabs
  • CELLeBRAIN
  • Cellipont Bioservices
  • Celprogen, Inc.
  • CellProthera
  • CellResearch Corporation, Pte, Ltd.
  • Cell Surgical Network (CSN)
  • Celltex Therapeutics Corporation
  • CellTherapies
  • Cellular Biomedicine Group
  • Charles River Laboratories
  • CHIESI Farmaceutici SpA
  • Citius Pharmaceuticals, Inc.
  • CorestemChemon, Inc.
  • Creative Bioarray
  • Creative Medical Technology Holdings, Inc.
  • Curia Global, Inc
  • Cynata Therapeutics, Ltd
  • Cytovance Biologics
  • Defined Bioscience, Inc.
  • Direct Biologics
  • eQcell, Inc.
  • Excellos
  • Exosla Therapeutics
  • EXOSOMEplus
  • Exothera
  • Fujifilm Diosynth Biotechnologies
  • Future Cell Japan, Co., Ltd
  • Genezen
  • GenScript Biotech Corporation
  • Hope Biosciences, LLC
  • Implant Therapeutics, Inc
  • INCELL Corporation LLC
  • InGeneron GmbH
  • Invitrx Therapeutics
  • Japan Tissue Engineering, Co., Ltd. (J-TEC)
  • JCR Pharmaceuticals, Co., Ltd.
  • Jointechlabs
  • Kangstem Biotech, Co., Ltd
  • Kimera Labs
  • LifeCell
  • Longeveron
  • Lonza Group, Ltd
  • Lorem Cytori USA, Inc.
  • MEDPOST
  • Mesoblast, Ltd.
  • Millipore Sigma
  • NecstGen
  • NextCell
  • NIPRO Corporation
  • Novadip Biosciences
  • Novus Biologicals, LLC
  • NuVasive
  • OCT Therapies & Research Pvt., Ltd
  • OmniaBio, Inc.
  • Orthocell, Ltd
  • Orthofix Medical, Inc.
  • Ossium Health
  • Personal Cell Sciences Corporation
  • Personalized Stem Cells, Inc.
  • Pfizer CentreOne
  • Pluri Biotech, Ltd.
  • Porton Advanced
  • Prometheus Life Technologies
  • PromoCell GmbH
  • PuREC, Co., Ltd.
  • Regrow Biosciences
  • Reliance Life Sciences, Pvt., Ltd.
  • Remedy Cell, Ltd.
  • Rentschler Biopharma
  • REPROCELL USA, Inc
  • Resilence
  • RESTEM, LLC
  • RHEACELL GmbH &Co., KG
  • Richter-HELM
  • RoosterBio, Inc.
  • RTI Surgical
  • RoslinCT
  • Samsung Biologics
  • San Bio, Co., Ltd.
  • Smith & Nephew, Inc.
  • StemBioSys, Inc.
  • STEMCELL Technologies, Inc
  • Stemedica Cell Technologies, Inc.
  • Stemmatters
  • StemMedical
  • Stempeutics Research Pvt., Ltd
  • StromaBio AB
  • TaiwanBio Therapeutics, Co., Ltd.
  • Takeda Pharmaceutical, Co., Ltd
  • Tempo Bioscience
  • ThermoFisher Scientific
  • Vericel Corporation
  • Wuxi App Tec
  • Xintela AB

插圖索引

表格一覽

簡介目錄

EXECUTIVE SUMMARY

MSCs are multipotent cells that have been referred to as mesenchymal stem cells, medicinal signaling cells, and mesenchymal stromal cells, reflecting their versatility and diverse applications. MSCs can differentiate into a variety of cell types, such as osteoblasts, chondrocytes, myocytes, and adipocytes. Their unique ability to secrete factors that promote tissue repair and modulate their microenvironment with anti-inflammatory and anti-fibrotic effects makes them essential in regenerative medicine. Furthermore, their immuno-evasive properties make MSCs particularly suitable for allogenic transplantation.

MSCs serve as vital raw materials across numerous industries, including regenerative medicine, cosmeceuticals, and cultured meat production. Key applications include:

  • Cell-based therapies for musculoskeletal diseases, spinal injuries, and cardiovascular conditions.
  • Engineered tissues and organs, such as skin, bone, blood vessels, and liver.
  • Cell-derived products, such as exosomes and growth factors, utilized in cosmetics and skincare.
  • Cultured meat production, leveraging MSCs' role in muscle development and their ability to differentiate into muscle and fat cells.

Globally, 12 MSC-based therapies have been approved for various indications, with the majority concentrated in South Korea, Japan, and the EU.

Specifically, the Republic of Korea has approved five products: Queencell from Anterogen, Cellgram AMI from Pharmicell, Cupistem from Anterogen, Cartistem from Medipost, and NeuroNataR from Corestem. Japan has approved two products: Temcell HS from JCR Pharmaceuticals and Stemirac from Nipro Corporation. The EMA in Europe has approved two products: Holoclar from Chiesi Farmaceutici and Alofisel from TiGenix/Takeda. India has approved one product: Stempeucel from Stempeutics. Iran has approved one product: MesestroCell developed by Cell Tech Pharmed. Finally, Australia has approved one product: Remestemcel-L from Mesoblast.

Despite this progress, no MSC-based therapeutic have yet received U.S. FDA approval, although the FDA is actively reviewing Mesoblast's Remestemcel-L.

The cosmeceutical market is also rapidly adopting MSC-derived products, particularly exosomes, to leverage their anti-aging and regenerative properties, with companies like L'Oreal and Johnson & Johnson investing heavily in this space. Similarly, cultured meat companies are utilizing MSCs for producing muscle and fat cells, enhancing taste and texture. Groundbreaking approvals, such as lab-grown chicken by Upside Foods and Good Meat, have paved the way for further growth in this industry.

MSC-based gene editing is expanding, enabling the overexpression of antitumor genes and therapeutic factors. Researchers are also exploring the use of MSCs in 3D printing and engineered organ production, with breakthroughs anticipated in the next decade.

Importantly, companies like Cynata Therapeutics are pioneering iPSC-derived MSC production technologies, enabling large-scale therapeutic development. Today there are at least eight companies who are involved with the development of iPSC-derived MSCs therapeutics (iMSCs), including Cynata Therapeutics, Eterna Therapeutics, Implant Therapeutics, Bone Therapeutics, Brooklyn ImmunoTherapeutics, Fujifilm CDI, Citius Pharmaceuticals, and Kiji Therapeutics.

There are also over 1,670 clinical trials involving MSCs are registered on ClinicalTrials.gov. Nearly 75% (three-quarters) of these clinical studies are using MSCs for the development of regenerative medicine (RM) products. Approximately 14% of the studies are using MSCs for disease modeling. The remaining 11% of the studies are using MSCs for drug discovery and cytotoxicity testing applications.

Challenges in these trials include maintaining MSC phenotype and functionality during expansion. However, ongoing advancements suggest a promising future, with projections for at least 50 globally approved MSC-based products by 2040, averaging 3-4 new approvals annually.

Key Players in MSC Research Products

The demand for MSC-based research products has surged in recent years, with major suppliers expanding their portfolios. Companies like RoosterBio have increased the access to quality MSCs through supply chain industrialization, standardized cell bank product forms, and fit-for-purpose cGMP-compatible cells and media systems.

Other leading MSC research product suppliers include PromoCell, Lonza, Thermo Fisher Scientific, STEMCELL Technologies, Miltenyi Biotec, Bio-Techne (R&D Systems), ScienCell Research Laboratories, and the ATCC.

Challenges and Opportunities

While MSC commercialization faces hurdles-such as scalability and regulatory approval-opportunities abound. The market for MSC-based products is poised for notable growth across the research, therapeutic, cosmetic, and food industries.

Within this rapidly changing landscape, having a thorough understanding of the competition is essential.

This global strategic report presents rates of MSC clinical trials, scientific publications, patents, funding events, and collaborations. It presents the pipeline for MSC-based therapeutics, identifies market opportunities and threats, and explores future directions and emerging applications. It reveals innovative MSC products, services, and technologies offered by 125 leading competitors. Finally, it presents detailed market size figures for the global MSC market, segmented by geography and business segment with future forecasts through 2031.

TABLE OF CONTENTS

1. REPORT OVERVIEW

  • 1.1 Statement of the Report
  • 1.2 Target Demographic
  • 1.3 Sources for this Report
  • 1.4 Purpose of the Report
    • 1.4.1 Survey Recent Advancements
    • 1.4.2 Provide a Summary of the Global MSC Market
    • 1.4.3 Access Opportunities for Commercialization
    • 1.4.4 Identify Major Market Players and Evaluate the Competitive Environment
    • 1.4.5 Identify Existing and Emerging Trends
    • 1.4.6 Identify Critical Opportunities and Threats within the MSC Market
  • 1.5 Executive Summary
  • 1.6 Introduction

2. MESENCHYMAL STEM CELLS (MSCs): AN OVERVIEW

  • 2.1 Stabilization of Human MSCs (hMSCs) as a Technology
  • 2.2 The Impact of MSCs on Regenerative Medicine
  • 2.3 Timeline of MSC Nomenclature
  • 2.4 Sources of MSCs
    • 2.4.1 Bone Marrow-Derived MSCs (BM-MSCs)
    • 2.4.2 Adipose-Derived MSCs (AD-MSCs)
    • 2.4.3 Umbilical Cord-Derived MSCs (UC-MSCs)
    • 2.4.4 iPSC-Derived MSCs (iMSCs)
  • 2.5 Cell Surface Markers in MSCs
  • 2.6 In vitro Differentiation Potentials of MSCs
  • 2.7 Soluble Factors Secreted by MSCs
  • 2.8 Stemness Genes Present in MSCs
  • 2.9 Types of MSCs and their Biomedical Applications
  • 2.10 Genes that are Pivotal for MSCs' Properties

3. MSC-BASED CLINICAL TRIAL LANDSCAPE

  • 3.1 MSC-Based Clinical Studies by Geography
  • 3.2 Sources of MSCs used in Current Clinical Trials
  • 3.3 Share of Autologous & Allogeneic MSCs Clinical Trials
  • 3.4 MSC-Based Clinical Trials by Disease Indication
  • 3.5 MSC-Based Clinical Trials by Phase of Study
  • 3.6 Select MSC-Based Clinical Trials
    • 3.6.1 MSC-Based Clinical Trials for Musculoskeletal Disorders
    • 3.6.2 MSC-Based Clinical Trials for Neurological Disorders
    • 3.6.3 Clinical Trials involving MSC-Derived Exosomes
    • 3.6.4 Primed MSCs in Clinical Trials
    • 3.6.5 Clinical Trials involving Scaffold-Based MSCs

4. MESENCHYMAL STEM CELLS (MSCS): PATENT LANDSCAPE

  • 4.1 MSC Patent Publications by Jurisdiction
  • 4.2 MSC Patent Applicants
  • 4.3 MSC Patent Inventors
  • 4.4 MSC Patent Owners
  • 4.5 Legal Status of MSC Patent Applications
  • 4.6 MSC-Derived Exosome Patents
    • 4.6.1 MSC-Derived Exosome Patents by Jurisdiction
    • 4.6.2 MSC-Derived Exosome Patent Applicants
    • 4.6.3 MSC-Derived Exosome Patent Inventors
    • 4.6.4 MSC-Derived Exosome Patent Owners
    • 4.6.5 Legal Status of MSC-Derived Exosome Patents
  • 4.7 Patents for iPSC-Derived MSCs (iMSCs)
    • 4.7.1 iPSC-Derived MSC Patents by Jurisdiction
    • 4.7.2 iPSC-Derived MSC Patent Owners
  • 4.8 MSC Patents by Therapy Type

5. PUBLISHED SCIENTIFIC PAPERS ON MSCS

  • 5.1 PubMed.gov Published Papers on MSCs in Cell Therapy
  • 5.2 PubMed.gov Published Papers on MSC-Based Immunotherapies
  • 5.3 PubMed.gov Published Papers on MSCs in Gene Therapy
  • 5.4 PubMed.gov Published Papers on MSCs in Tissue Engineering
  • 5.5 PubMed.gov Published Papers on MSCs in Aesthetics
  • 5.6 Number of Published Papers on the Applications of MSCs in Major Diseases
  • 5.7 Published Papers on Modified MSCs
  • 5.8 Published Papers on MSC-Derived Exosomes

6. MSC MANUFACTURING PLATFORMS: AN OVERVIEW

  • 6.1 Methods of Isolations of MSCs
  • 6.2 Cell Expansion: Conventional Cultures to Bioreactors
    • 6.2.1 Monolayer Culture Systems
    • 6.2.2 Bioreactor-Based Cell Expansion
      • 6.2.2.1 Stirred Tank Bioreactor
      • 6.2.2.2 Rocking Bioreactor
      • 6.2.2.3 Hollow Fiber Bioreactors
      • 6.2.2.4 Fixed-Bed Bioreactor
    • 6.2.3 Bioreactors in Current Use
      • 6.2.3.1 Automated Platforms
      • 6.2.3.2 Miniaturized Bioreactors
      • 6.2.3.3 Verical-Wheel Bioreactors
    • 6.2.4 MSC Expansion Systems: A Snapshot
    • 6.2.5 Number of Cells per batch by Technologies
    • 6.2.6 Microcarriers used for Cell Expansion
  • 6.3 Downstream Processing of MSCs
    • 6.3.1 Cell Detachment and Separation (Harvesting)
    • 6.3.2 Cell Washing and Concentration
    • 6.3.3 Safety and Potency Assays
    • 6.3.4 Surface Markers for Distinguishing MSCs from Fibroblasts
  • 6.4 Autologous & Allogeneic MSC Manufacturing: A Comparison
    • 6.4.1 Cost of Manufacturing Allogeneic MSCs
    • 6.4.2 Cost of Manufacturing Autologous MSCs
    • 6.4.3 Cost of Donor Screening & Testing
    • 6.4.4 Cost of Release Testing
  • 6.5 Large Scale Manufacturing of MSCs
    • 6.5.1 MSC Manufacturing Platforms
      • 6.5.1.1 Quantum Cell Expansion System
      • 6.5.1.2 CliniMACS Prodigy
      • 6.5.1.3 NANT 001
      • 6.5.1.4 CellQualia
      • 6.5.1.5 Cocoon
      • 6.5.1.6 Xuri Cell Expansion System W25
    • 6.5.2 Scaling Up of Cell Culture Vessels
      • 6.5.2.1 CellSTACK Multilayered Flasks
      • 6.5.2.2 Nunc Cell Factory Systems
      • 6.5.2.3 HYPERFlask Vessels
      • 6.5.2.4 HYPERStack
      • 6.5.2.5 CellCube System
    • 6.5.3 Culture Medium
      • 6.5.3.1 Expansion Ratios Achieved with Different Culture Media
    • 6.5.4 Cryopreservation of MSCs

7. CELL & GENE THERAPY CONTRACT MANUFACTURING

  • 7.1 Staff Shortage
  • 7.2 Need for Automation
  • 7.3 Capacity Constraints
  • 7.4 CDMO Platforms with Greater Potentials
    • 7.4.1 Type of CDMOs Used by Sponsors
  • 7.5 CMOs/CDMOs
    • 7.5.1 Contract Manufacturing Organizations (CMOs)
      • 7.5.1.1 Major Services Offered by CMOs
    • 7.5.2 Contract Development and Manufacturing Organizations (CDMOs)
      • 7.5.2.1 Major CDMOs
      • 7.5.2.2 Major Services offered by CDMOs
  • 7.6 Geographic Distribution of Manufacturing Facilities
  • 7.7 Continued Rise of Outsourcing
    • 7.7.1 Specific Areas of Outsourcing
    • 7.7.2 Select Services for Outsourcing
    • 7.7.3 Expected Rate of Outsourcing Increase
  • 7.8 Major CDMOs in the U.S.
  • 7.9 Major Cell & Gene Therapy CDMOs in Europe
  • 7.10 UK's Dominance in European Contract Manufacturing
    • 7.10.1 GMP Manufacturing in U.K.
    • 7.10.2 Cleanroom Footprint in UK
    • 7.10.3 Cell Therapy Process Capabilities in U.K.
    • 7.10.4 U.K.'s Gene Therapy Process Capabilities
    • 7.10.5 Future CDMO Capacity and Expansion within the UK

8. BIOENGINEERING SOLUTIONS TO BOOST MSC FUNCTIONALITY

  • 8.1 Small Molecule Priming of MSCs
  • 8.2 Particle Engineering of MSCs
    • 8.2.1 Materials used in Microparticles (MPs) Fabrication
  • 8.3 Genetic Engineering of MSCs
    • 8.3.1 Engineered MSCs as Living Drug Factories
  • 8.4 Examples of Bioengineered MSCs to Produce Anticancer Therapeutics
  • 8.5 Engineered MSCs for Neurological Conditions
  • 8.6 Engineered MSCs for Cardiovascular Diseases
  • 8.6 Engineered MSCs for Lung Injury
  • 8.7 Engineered MSCs for Diabetes
  • 8.8 Bioengineering Approaches to Improve MSC Administration

9. MAJOR DISEASES ADDRESSED BY MSCS

  • 9.1 Studies Using MSCs for Autoimmune Diseases
  • 9.2 Studies using MSCs for Cardiovascular Diseases
  • 9.3 Studies using MSCs for Neurodegenerative Diseases
  • 9.4 Studies using MSCs for Bone & Cartilage Diseases
  • 9.5 Studies using MSCs in GvHD
  • 9.6 Studies using MSCs in Crohn's Disease
  • 9.7 Studies using MSCs in Type 1 Diabetes
  • 9.8 Studies using MSCs in Systemic Lupus Erythematosus (SLE)
  • 9.9 Studies using MSCs in Parkinson's Disease
  • 9.10 Studies using MSCs in Alzheimer's Disease
  • 9.11 Studies using MSCs in Kidney Failure
  • 9.12 Studies using MSCs in Spinal Cord Injury
  • 9.13 Studies using MSCs for Wound Healing

10. RECENT COLLABORATIONS WITHIN THE MSC SECTOR, 2020-2024

  • 10.1 Collaboration between BioSolution Designs & RoosterBio
  • 10.2 Collaboration between CytoMed Therapeutics, Ltd. & Sengkang General Hospital
  • 10.3 Collaboration between REPROCELL & Histocell
  • 10.4 Collaboration between FUJIFILM Diosynth & RoosterBio
  • 10.5 RoosterBio's Collaboration with AGC Biologics
  • 10.6 RoosterBio's Partnership with ShiftBio
  • 10.7 RoosterBio's Partnership with Univercells Technologies
  • 10.8 Collaboration between Cynata & Fujifilm
  • 10.9 Collaboration between American CryoStem Corp. & BioTherapeutic Lab Corp.
  • 10.10 RoosterBio's Collaboration with Sartorius
  • 10.11 Collaboration between American CryoStem and CRADA
  • 10.12 RoosterBio's Collaboration with Sartorius Korea Biotech
  • 10.13 Collaboration between Catalent & BrainStorm
  • 10.14 Collaboration between Cipla & Stempeutics
  • 10.15 Aethlon's Collaboration with University of Pittsburgh
  • 10.16 RoosterBio's Collaboration with Senti Biosciences

11. MSC-BASED PRODUCTS IN THE GLOBAL MARKET

  • 11.1 Approved MSC Therapies
    • 11.1.1 Queencell
    • 11.1.2 Cellgram AMI
    • 11.1.3 Cupistem
    • 11.1.4 Cartistem
    • 11.1.5 NeuroNataR
    • 11.1.6 Holoclar
    • 11.1.7 Prochymal / Ryoncil (remestemcel-L)
    • 11.1.8 Temcell HS
    • 11.1.9 Stempeucel
    • 11.1.10 MesestroCell
    • 11.1.11 Stemirac
    • 11.1.12 Ruibosheng (amimestrocel)
  • 11.2 Marketed Biomaterial Carrier-Based MSCs & MSC Progenitors
    • 11.2.1 Osteocel
    • 11.2.2 AlloStem
    • 11.2.3 Grafix
    • 11.2.4 Cellentra VCBM
    • 11.2.5 Trinity ELITE
    • 11.2.6 Map3
    • 11.2.7 BIO4
    • 11.2.8 Trinity Evolution
    • 11.2.9 Carticel
    • 11.2.10 Chondron
    • 11.2.11 DeNovo NT
    • 11.2.12 Ossron
    • 11.2.13 JACC
    • 11.2.14 MACI
    • 11.2.15 Ortho-ACI
    • 11.2.16 Ossgrow
    • 11.2.17 Cartigrow
  • 11.3 Topical Cosmetic Products Containing MSCs/MSC-Derived Exosomes

12. MARKET ANALYSIS

  • 12.1 Market Size for MSC Therapies
  • 12.2 Global Demand for Mesenchymal Stem Cells (MSCs)
    • 12.2.1 Global Demand for MSCs in Academic and Preclinical Studies
    • 12.2.2 Global Demand for MSCs in Clinical Trials
    • 12.2.3 Global Demand for MSCs for Developing MSC Therapeutics
    • 12.2.4 Global Demand for MSCs to Develop Exosome Products
    • 12.2.5 Global Demand for MSCs in Emerging Industries
    • 12.2.6 Global Market for Mesenchymal Stem Cells (MSCs)
    • 12.2.7 Global MSC Market by Application

13. COMPANY PROFILES

  • 13.1 Advancells
    • 13.1.1 MSC-Derived Exosome Therapy
  • 13.2 Aegle Therapeutics
    • 13.2.1 Dystrophic Epidermolysis Bullosa
    • 13.2.2 Burns/Scarring
    • 13.2.3 Additional Indications
  • 13.3 AGC Biologics
    • 13.3.1 Cell Therapy Manufacturing
    • 13.3.2 Services
  • 13.4 AlloSource, Inc.
    • 13.4.1 Allografts with Tissue-Derived MSCs
    • 13.4.2 Products
      • 13.4.2.1 AlloConnex
      • 13.4.2.2 AlloFuse & AlloFuse Plus DBM
      • 13.4.2.3 AlloFlex Plus
      • 13.4.2.4 AlloFuse Cervical Grafts
      • 13.4.2.5 AlloFuse Fiber and Fiber Boats
      • 13.4.2.6 AlloFuse Select CM
  • 13.5 Ambulero
    • 13.5.1 Supercharged MSCs
    • 13.5.2 Ambulero's Pipeline
  • 13.6 American CryoStem Corporation
    • 13.6.1 Adult Stem Cell Storage Service
    • 13.6.2 Products Offered
      • 13.6.2.1 CELLECT
      • 13.6.2.2 ACSelerateMAX
      • 13.6.2.3 ATCELL
  • 13.7 American Type Culture Collection (ATCC)
    • 13.7.1 Stem Cell Products
  • 13.8 Amniotics
    • 13.8.1 Technology
    • 13.8.2 Product Pipeline
  • 13.9 Andelyn Biosciences
    • 13.9.1 Andelyn's Solutions
  • 13.10 Anemocyte S.r.l
    • 13.10.1 GMP Capacity
    • 13.10.2 Product Types
    • 13.10.3 Manufacturing Services
  • 13.11 Anterogen, Co., Ltd.
    • 13.11.1 Products
      • 13.11.1.1 Cupistem Injection
      • 13.11.1.2 Queencell
  • 13.12 Avid Bioservices, Inc.
    • 13.12.1 Services
  • 13.13 Bacthera
    • 13.13.1 Services
  • 13.14 Baylx, Inc.
    • 13.14.1 Technology
    • 13.14.2 Product Pipeline
      • 13.14.2.1 BX-U001 for Rheumatoid Arthritis
  • 13.15 BioCardia
    • 13.15.1 Product Pipeline
  • 13.16 BioCentriq
    • 13.16.1 Clinical Manufacturing Services
    • 13.16.2 Process Development Services
  • 13.17 BioEden, Inc.
  • 13.18 Bioinova s.r.o
    • 13.18.1 Products
    • 13.18.2 Services
      • 13.18.2.1 Storage & Transportation Solution
      • 13.18.2.2 Cryopreservation
      • 13.18.2.3 Autologous Therapy
      • 13.18.2.4 Allogeneic Therapy
  • 13.19 BioRestorative Therapies
    • 13.19.1 BRTX-100
    • 13.19.2 ThermoStem
  • 13.20 Bioscience Institute S.p.A
    • 13.20.1 Aesthetic Stem Cells
      • 13.20.1.1 LIPOSKILL for Skin Rejuvenation
      • 13.20.1.2 LIPOSKILL PLUS for Face Reshaping
      • 13.20.1.3 LIPOSKILL PLUS for Breast Augmentation
      • 13.20.1.4 LIPOSKILL PLUS for Buttock Enhancement
      • 13.20.1.5 LIPOSKILL PLUS for Reduction of Scars and Stretch Marks
      • 13.20.1.6 HAIRSKILL for Hair Loss Treatment
      • 13.20.1.7 GYNSKILL for Vulvo-Vaginal Rejuvenation
    • 13.20.2 Regenerative Stem Cells
      • 13.20.2.1 ORTHOSKILL for Regenerative Orthopedics
      • 13.20.2.2 OVOSKILL for Early Menopause Treatment
      • 13.20.2.3 ANDROSKILL for Erectile Dysfunction Treatment
      • 13.20.2.4 Anti-Aging IV Therapy
      • 13.20.2.5 XEROSTOMIA Treatment
      • 13.20.2.6 Empty Nose Syndrome (ENS) Treatment
      • 13.20.2.7 Stem Cell Therapy for Body Performance
  • 13.21 Blue Horizon International, LLC
    • 13.21.1 BHI's Stem Cell Division
  • 13.22 Boehringer Ingelheim BioXellence
    • 13.22.1 Services
  • 13.23 Bonus Biogroup, Ltd.
    • 13.23.1 BonoFill
    • 13.23.2 MesenCure
  • 13.24 BrainStorm Cell Therapeutics, Inc.
    • 13.24.1 NurOwn Technology
    • 13.24.2 Manufacturing of NurOwn
    • 13.24.3 BrainStorm's Clinical Trials
  • 13.25 Catalent
    • 13.25.1 Cell Therapy Process Development
    • 13.25.2 Cell Therapy CGMP Manufacturing
  • 13.26 CCRM
  • 13.27 Cell2Cure ApS
    • 13.27.1 Product
      • 13.27.1.1 Mode of Action
      • 13.27.1.2 Manufacture
  • 13.28 Cell Care Therapeutics
    • 13.28.1 Platform
    • 13.28.2 CCT-101
  • 13.29 Cellcolabs
    • 13.29.1 Ordering Cells
  • 13.30 CELLeBRAIN
    • 13.30.1 Core Technology
    • 13.30.2 CELLeBRAIN's Product Pipeline
  • 13.31 Cellipont Bioservices
    • 13.31.1 Cellipont's Capabilities
    • 13.33.2 Cellipont's Cell Expertise
  • 13.34 Celprogen, Inc.
    • 13.34.1 Products
    • 13.34.2 Services
  • 13.35 CellProthera
    • 13.35.1 ProtheraCytes
    • 13.35.2 Technology: StemXpand
  • 13.36 CellResearch Corporation, Pte, Ltd.
    • 13.36.1 Umbilical Cord Lining Stem Cells
    • 13.36.2 CALECIM
  • 13.37 Cell Surgical Network (CSN)
    • 13.37.1 Technology: The Time Machine 3.0 Auto
    • 13.37.2 Time Machine Process
  • 13.38 Celltex Therapeutics Corporation
    • 13.38.1 Therapy Services
  • 13.39 CellTherapies
    • 13.39.1 Services
    • 13.39.2 Contract Manufacturing
    • 13.39.3 Apheresis Management
    • 13.39.4 Clinical Trial Support
  • 13.40 Cellular Biomedicine Group
  • 13.41 Charles River Laboratories
    • 13.41.1 Cell Therapy Manufacturing Services
  • 13.42 CHIESI Farmaceutici S.p.A
    • 13.42.1 Holoclar
  • 13.43 Citius Pharmaceuticals, Inc.
    • 13.43.1 Stem Cell Platform
  • 13.44 CorestemChemon, Inc.
    • 13.44.1 Neuronata-R inj.
  • 13.45 Creative Bioarray
    • 13.45.1 MSC Services
    • 13.45.2 MSC Isolation and Expansion Services
    • 13.45.3 MSC Characterization Services
    • 13.45.4 MSC Differentiation Services
  • 13.46 Creative Medical Technology Holdings, Inc.
    • 13.46.1 Rapid Autologous Therapies
    • 13.46.2 Creative Medical's Preclinical and Clinical Pipeline
  • 13.47 Curia Global, Inc
    • 13.47.1 Services
  • 13.48 Cynata Therapeutics, Ltd.
    • 13.48.1 Cymerus Platform
      • 13.48.1.1 CYP-001
      • 13.48.1.2 CYP-004
      • 13.48.1.3 Cymerus MSCs for ARDS
      • 13.48.1.4 CYP-006TK
  • 13.49 Cytovance Biologics
    • 13.49.1 GMP Manufacturing
  • 13.50 Defined Bioscience, Inc.
    • 13.50.1 Products
      • 13.50.1.1 Applications in Stem Cells
      • 13.50.1.2 Applications in Cultivated Meat
  • 13.51 Direct Biologics
    • 13.51.1 ExoFlo
  • 13.52 eQcell, Inc.
    • 13.52.1 Innovation
  • 13.53 Excellos
  • 13.54 Exosla Therapeutics
  • 13.55 EXOSOMEplus
  • 13.56 Exothera
    • 13.56.1 Exoscan Process Analysis Services
    • 13.56.2 Process Design & Development Services
    • 13.56.3 GMP Manufacturing Services
  • 13.57 Fujifilm Diosynth Biotechnologies
    • 13.57.1 Cell & Gene Therapy Services
  • 13.58 Future Cell Japan, Co., Ltd.
    • 13.58.1 Conditioned Media from UC-MSCs
  • 13.59 Genezen
    • 13.59.1 Genezen's Capabilities
  • 13.60 GenScript Biotech Corporation
    • 13.60.1 Cell Therapy Product Solutions
      • 13.60.1.1 CytoSinct Nanobeads
      • 13.60.1.2 CytoSinct Manual Separator System
      • 13.60.1.3 CytoSinct 1000
  • 13.61 Hope Biosciences, LLC
    • 13.61.1 Adult Stem Cell Banking
    • 13.61.2 Newborn Stem Cell Banking
    • 13.61.3 Sponsored Clinical Trials
  • 13.62 Implant Therapeutics, Inc.
    • 13.62.1 Services
  • 13.63 INCELL Corporation LLC
    • 13.63.1 Product Line
    • 13.63.2 Cell & Tissue Products
    • 13.63.3 Tissue Collections & Kit Products
    • 13.63.4 Storage of Cell & Tissue Products
  • 13.64 InGeneron GmbH
    • 13.64.1 Transpose RT Process
    • 13.64.2 Adipose-Derived Regenerative Cells (ADRCs)
  • 13.65 Invitrx Therapeutics
    • 13.65.1 Reluma
  • 13.66 Japan Tissue Engineering, Co., Ltd. (J-TEC)
    • 13.66.1 JACC
  • 13.67 JCR Pharmaceuticals, Co., Ltd.
    • 13.67.1 TEMCELL HS Inj.
  • 13.68 Jointechlabs
    • 13.68.1 Products
      • 13.68.1.1 MiniTC
      • 13.68.1.2 Mini-Stem
    • 13.68.2 Jointech's Products in Pipeline
      • 13.68.2.1 JTL-T-01 (Osteoarthritis Clinical Therapy)
      • 13.68.2.2 JTL-T-02 (Wounds Clinical Therapy)
  • 13.69 Kangstem Biotech, Co., Ltd.
    • 13.69.1 Stem Cell Therapeutics
    • 13.69.2 Stem Cell Therapy
  • 13.70 Kimera Labs
    • 13.70.1 Vive
    • 13.70.2 Luxir
  • 13.71 LifeCell
    • 13.71.1 Large-Scale Manufacturing of MSCs
  • 13.72 Longeveron
    • 13.72.1 Lomecel-B
    • 13.72.2 Clinical Pipeline
  • 13.73 Lonza Group, Ltd
    • 13.73.1 Sell& Gene Technologies Segment
    • 13.73.2 Bioscience Segment
    • 13.73.3 Personalized Medicines Segment
  • 13.74 Lorem Cytori USA, Inc.
    • 13.74.1 Celution System
    • 13.74.2 Cytori Cell Therapy
  • 13.75 MEDPOST
    • 13.75.1 Products
      • 13.75.1.1 CARTISTEM
      • 13.75.1.2 PNEUMOSTEM
      • 13.75.1.3 SMUP-IA-01
      • 13.75.1.4 SMUP-IV-01
  • 13.76 Mesoblast, Ltd.
    • 13.76.1 Technology Platform
    • 13.76.2 Intellectual Property Estate
    • 13.76.3 Product Candidates
      • 13.76.3.1 Revascor
      • 13.76.3.2 MPC-06-ID
      • 13.76.3.3 Remestemcel-L
      • 13.76.3.4 MPC-300-IV
  • 13.77 Millipore Sigma
    • 13.77.1 Cell Culture & Analysis Products
  • 13.78 NecstGen
    • 13.78.1 Cell Therapy Development & Manufacturing
    • 13.78.2 Viral Vector Development & Manufacturing
    • 13.78.3 Cleanroom Rental
  • 13.79 NextCell
    • 13.79.1 ProTrans
    • 13.79.2 Cellaviva
    • 13.79.3 NextCell's Products in Pipeline
  • 13.80 NIPRO Corporation
    • 13.80.1 Stemirac
  • 13.81 Novadip Biosciences
    • 13.81.1 The 3M3 Platform
    • 3.81.2 Products
      • 13.81.2.1 3MAUTO
      • 13.81.2.2 3MALLO
      • 13.81.2.3 3MEXO
  • 13.82 Novus Biologicals, LLC
  • 13.83 NuVasive
    • 13.83.1 Osteocel Portfolio
      • 13.83.1.1 Osteocel Plus
      • 13.83.1.2 Osteocel Pro
  • 13.84 OCT Therapies & Research Pvt., Ltd
  • 13.85 OmniaBio, Inc.
    • 13.85.1 Services
      • 13.85.1.1 Process Development
      • 13.85.1.2 GMP Manufacturing
      • 13.85.1.3 Analytical Development
      • 13.85.1.4 Regulatory Guidance
  • 13.86 Orthocell, Ltd.
    • 13.86.1 OrthoACI
  • 13.87 Orthofix Medical, Inc.
    • 13.87.1 Trinity Elite
    • 13.87.2 Trinity Evolution
  • 13.88 Ossium Health
    • 13.88.1 Platform
    • 13.88.2 Applications
      • 13.88.2.1 Hematologic Diseases
      • 13.88.2.2 Organ Transplant Rejection
      • 13.88.2.3 Musculoskeletal Defects
    • 13.88.3 Products
      • 13.88.3.1 OssiGraft Prime
      • 13.88.3.2 OssiGraft
      • 13.88.3.3 GMP Human Mesenchymal Stem Cells
      • 13.88.3.4 GMP Human Selected CD34+ Cells
      • 13.88.3.5 RUO Mesenchymal Stem Cells
      • 13.88.3.6 RUO Human Selected CD34+ Cells
  • 13.89 Personal Cell Sciences Corporation
    • 13.89.1 Autokine CM
    • 13.89.2 Products
  • 13.90 Personalized Stem Cells, Inc.
    • 13.90.1 Personalized Stem Cells for Knee Osteoarthritis
  • 13.91 Pfizer CentreOne
    • 13.91.1 Manufacturing
  • 13.92 Pluri Biotech, Ltd.
    • 13.92.1 PLX Products
  • 13.93 Porton Advanced
    • 13.93.1 Cell Therapy Services
    • 13.93.2 LVV Services
    • 13.93.3 PLX-PAD
    • 13.93.4 PLX-R18
    • 13.93.5 PLX-Immune
  • 13.94 Prometheus Life Technologies
    • 13.94.1 Organoids
  • 13.95 PromoCell GmbH
    • 13.95.1 Products
  • 13.96 PuREC, Co., Ltd.
    • 13.96.1 PuREC Solution for Hypophosphatasia
    • 13.96.2 PuREC Solution for Spinal Canal Stenosis
  • 13.97 Regrow Biosciences
    • 13.97.1 Ossgrow
    • 13.97.2 Cartigrow
  • 13.98 Reliance Life Sciences, Pvt., Ltd.
    • 13.98.1 Regenerative Medicine Products
  • 13.99 Remedy Cell, Ltd.
    • 13.99.1 Proprietary Platform
    • 13.99.2 Drug Candidate: RC-0315
  • 13.100 Rentschler Biopharma
    • 13.100.1 Services
  • 13.101 REPROCELL USA, Inc.
    • 13.101.1 Services
    • 13.101.2 Products
  • 13.102 Resilence
    • 13.102.1 Resilience's Capabilities
  • 13.103 RESTEM, LLC
    • 13.103.1 Umbilical Cord Lining Stem Cells (ULSCs)
    • 13.103.2 Muscular Dystrophy - Clinical Trial
    • 13.103.3 Dermatomyositis & Polymyositis - Clinical Trial
    • 13.103.3 Heart Failure - Clinical Trial
  • 13.104 RHEACELL GmbH & Co., KG
    • 13.104.1 Technology
    • 13.104.2 ABCB5+MSCs
  • 13.105 Richter-HELM
    • 13.105.1 Services
  • 13.106 RoosterBio, Inc.
    • 13.106.1 Technology
    • 13.106.2 Products
      • 13.106.2.1 Human Mesenchymal Stem Cells (hMSCs)
    • 13.106.3 Genetic Engineering Tools
      • 13.106.3.1 Genetic Engineering Media
    • 13.106.4 Cell Culture Media & Supplements
    • 13.106.5 Cell & Media Kits
    • 13.106.6 MSC-Derived Exosomes
    • 13.106.7 cGMP CliniControl Products
    • 13.106.8 Process Development Services
    • 13.106.9 hMSC Analytical Services
  • 13.107 RTI Surgical
    • 13.107.1 Map3
  • 13.108 RoslinCT
    • 13.108.1 Services
      • 13.108.1.1 Process Development
      • 13.108.1.2 GMP Manufacturing
      • 13.108.1.3 Quality Control
      • 13.108.1.4 Quality & Regulations
      • 13.108.1.5 Product Storage & Logistics
    • 13.108.2 RoslinCT-Lykan Bioscience Combine
  • 13.109 Samsung Biologics
    • 13.109.1 Contract Manufacturing Capabilities
  • 13.110 San Bio, Co., Ltd.
    • 13.110.1 SB623
  • 13.111 Smith & Nephew, Inc.
    • 13.111.1 Grafix
  • 13.112 StemBioSys, Inc.
    • 13.112.1 CELLvo Matrix Technology
    • 13.112.2 CELLVO hAD-MSCs
    • 13.112.3 CELLvo hBM-MSCs
    • 13.112.4 CELLvo hWJ-MSCs
    • 13.112.5 CELLvo Amniotic Membrane MSCs
  • 13.113 STEMCELL Technologies, Inc.
    • 13.113.1 Products
      • 13.113.1.1 MSC & MSC Progenitor Cell Research Products
  • 13.114 Stemedica Cell Technologies, Inc.
    • 13.114.1 BioSmart Technology
    • 13.114.2 Research & Development
  • 13.115 Stemmatters
  • 13.116 StemMedical
    • 13.116.1 Stemform Procedure
    • 13.116.2 Therapeutics Development
  • 13.117 Stempeutics Research Pvt., Ltd.
    • 13.117.1 Stempeucel
  • 13.118 StromaBio AB
    • 13.118.1 MSC Platform
  • 13.119 TaiwanBio Therapeutics, Co., Ltd.
  • 13.120 Takeda Pharmaceutical, Co., Ltd.
    • 13.120.1 Alofisel
  • 13.121 Tempo Bioscience
    • 13.121.1 Tempo iMSCs
  • 13.122 ThermoFisher Scientific
    • 13.122.1 CDMO Services for Cell Therapy
  • 13.123 Vericel Corporation
    • 13.123.1 MACI
  • 13.124 Wuxi App Tec
    • 13.124.1 CTDMO Services
  • 13.125 Xintela AB
    • 13.125.1 Technology Platform
    • 13.125.2 Stem Cell Products
      • 13.125.2.1 XSTEM
      • 13.125.2.2 EQSTEM
      • 13.125.2.3 Cancer Therapy

INDEX OF FIGURES

  • FIGURE 2.1: Mesenchymal Stem Cells and Their Derivatives
  • FIGURE 3.1: Number of Registered MSC-Based Clinical Trials, 1995- Jan, 2025
  • FIGURE 3.2: MSC-Based Clinical Trials by Region
  • FIGURE 3.3: MSC-Based Clinical Trials by Cell Source, Jan- 2025
  • FIGURE 3.4: Share of Autologous & Allogeneic MSCs in Clinical Trials
  • FIGURE 3.5: MSC-Based Clinical Trials by Indication
  • FIGURE 3.6: Percent Share of MSC-Based Clinical Trials by Phase of Study
  • FIGURE 4.1: MSC Patent Publications Over Time, 2000-Jan 7, 2025
  • FIGURE 4.2: MSC-Derived Exosome Patent Publications over Time
  • FIGURE 4.3: iPSC-Derived MSCs Patent Publications over Time
  • FIGURE 4.4: MSC Patents by Applications
  • FIGURE 5.1: Published Papers in PubMed.gov on Mesenchymal Stem Cells (MSCs)
  • FIGURE 5.2: PubMed.gov Published Papers on MSCs in Cell Therapy
  • FIGURE 5.3: PubMed.gov Published Papers on MSC-Based Immunotherapies
  • FIGURE 5.4: PubMed.gov Published Papers on MSCs in Gene Therapy
  • FIGURE 5.5: PubMed.gov Published Papers on MSCs in Tissue Engineering
  • FIGURE 5.6: PubMed.gov Published Papers on MSCs in Aesthetics
  • FIGURE 5.7: PubMed Published Papers on Major Ten Diseases addressed by MSCs
  • FIGURE 5.8: Number of Published Papers on Modified MSCs
  • FIGURE 5.9: Number of Published Papers on MSC-Derived Exosomes
  • FIGURE 6.1: Advantages and Disadvantages of Autologous & Allogeneic MSCs
  • FIGURE 6.2: Monolayer Culture Systems
  • FIGURE 6.3: Stirred Tank Bioreactor
  • FIGURE 6.4: Rocking Bioreactor or Wave Bioreactor
  • FIGURE 6.5: Hollow Fiber Bioreactor
  • FIGURE 6.6: Fixed-Bed Reactor
  • FIGURE 6.7: CompacT SelecT System from Sartorius
  • FIGURE 6.8: DASbox Mini Bioreactor System
  • FIGURE 6.9: PBS-80 Vertical-Wheel Bioreactor
  • FIGURE 6.10: Number of Cells per batch by Technologies
  • FIGURE 6.11: Overview of Bioprocessing Strategies for Large-Scale Production of MSCs
  • FIGURE 7.1: CDMO Platforms with Greater Potentials
  • FIGURE 7.2: Type of CDMOs Used by Sponsors
  • FIGURE 7.3: Major Services Offered by CMOs
  • FIGURE 7.4: Major Services used by Sponsors from CDMOs
  • FIGURE 7.5: Geographic Distribution of Manufacturing Facilities, 2017-2027
  • FIGURE 7.6: Percent Share of Outsourcing
  • FIGURE 7.7: Select Services for Outsourcing
  • FIGURE 7.8: Changing Priorities in Outsorcing Services between 2023 and 2025
  • FIGURE 7.9: Cleanroom Footprint in UK, 2018-2023
  • FIGURE 7.10: Cell Therapy Process Capabilities in U.K.
  • FIGURE 7.11: Gene Therapy Process Capabilities in U.K.
  • FIGURE 8.1: Bioengineering Solutions to Boost the Innate Functions of MSCs
  • FIGURE 8.2: Bioengineering Approaches to MSC Administration
  • FIGURE 9.1: Major Diseases Addresses by MSCs in Clinical Trials
  • FIGURE 9.2: Percentage Share of Autoimmune Diseases using MSCs in Clinical Trials
  • FIGURE 9.3: Percent Share of MSCs by Source in Trials for Cardiovascular Diseases
  • FIGURE 9.4: Percent Shares of Neurological Diseases in Clinical Trials using MSCs
  • FIGURE 9.5: Percent Shares of MSC-Based Musculoskeletal Studies by Source
  • FIGURE 12.1: Global Market for MSC-Based Therapeutics, 2023-2031
  • FIGURE 12.2: Global Market for Mesenchymal Stem Cells (MSCs)
  • FIGURE 12.3: Market Share of MSCs by Application
  • FIGURE 13.1: CELLeBRAIN's Core Technology
  • FIGURE 13.2: CALECIM
  • FIGURE 13.3: Schematic Diagram of CytoSinct Nanobeads
  • FIGURE 13.4: CytoSinct 1000
  • FIGURE 13.5: Why-iPSC Derived MSCs (iMSCs)
  • FIGURE 13.6: MiniTC
  • FIGURE 13.7: Mini-Stem

INDEX OF TABLES

  • TABLE 2.1: Timeline of MSC Nomenclature
  • TABLE 2.2: Sources of MSCs
  • TABLE 2.3: Advantages & Disadvantages of BM-MSCs
  • TABLE 2.4: Advantages & Disadvantages of AD-MSCs
  • TABLE 2.5: Advantages & Disadvantages of Umbilical Cord MSCs (UC-MSCs)
  • TABLE 2.6: Companies Developing iMSC Products
  • TABLE 2.7: Positive & Negative Markers in MSCs from Different Sources
  • TABLE 2.8: in vitro Differentiation Potentials of MSCs
  • TABLE 2.9: Soluble Factors Secreted by MSCs
  • TABLE 2.10: Some Typical "Stemness" Genes of MSCs
  • TABLE 2.11: Types of MSCs and their Biomedical Applications
  • TABLE 2.12: Genes that are Pivotal for MSCs' Properties
  • TABLE 3.1: MSC-Based Clinical Trials by Cell Source
  • TABLE 3.2: Select MSC-Based Clinical Trials
  • TABLE 3.3: Select MSC-Based Clinical Trials for Musculoskeletal Disorders
  • TABLE 3.4: Select MSC-Based Clinical Trials for Neurological Disorders
  • TABLE 3.5: Select Clinical Trials involving MSC-Derived Exosomes
  • TABLE 3.6: Primed MSCs in Clinical Trials
  • TABLE 3.7: Clinical Trials involving Scaffold-Based MSCs
  • TABLE 4.1: MSC Patent Records by Jurisdiction, January 7, 2025
  • TABLE 4.2: MSC Patent Applicants, January 7, 2025
  • TABLE 4.3: MSC Patent Inventors
  • TABLE 4.4: MSC Patent Owners
  • TABLE 4.5: Legal Status of MSC Patent Applications
  • TABLE 4.6: MSC-Derived Exosome Patents by Jurisdiction
  • TABLE 4.7: MSC-Derived Exosome Patent Applicants
  • TABLE 4.8: MSC-Derived Exosome Patent Inventors
  • TABLE 4.9: MSC-Derived Exosome Patent Owners
  • TABLE 4.10: Legal Status of MSC-Derived Exosome Patents
  • TABLE 4.11: iPSC-Derived MSC Patent Applications by Jurisdiction, August 2024
  • TABLE 4.12: iPSC-Derived MSC Patent Owners
  • TABLE 4.13: MSC Patents by Applications
  • TABLE 5.1: PubMed Published Papers on Major Ten Diseases addressed by MSCs
  • TABLE 5.2: Number of Published Papers on Modified MSCs
  • TABLE 5.3: Number of Published Papers on MSC-Derived Exosomes
  • TABLE 6.1: Methods of Isolations of MSCs
  • TABLE 6.2: A Snapshot of Commercially Available Culture Systems
  • TABLE 6.3: Microcarriers used for Cell Expansion
  • TABLE 6.4: Basic Assays for MSCs
  • TABLE 6.5: Cell Surface Markers on MSCs & Fibroblasts: A Comparison
  • TABLE 6.6: Cost of Manufacturing Allogeneic MSCs
  • TABLE 6.7: Cost of Manufacturing Autologous MSCs
  • TABLE 6.8: Media Used for GMP Grade MSC Production
  • TABLE 6.9: Expansion Ratios Achieved with Different Culture Media
  • TABLE 6.10: Commercially Available Controlled Freezing Systems for MSCs
  • TABLE 7.1: Top Ten CDMO Companies in 2003 & 2027
  • TABLE 7.2: GMP Capacities of U.S.-Based CDMOs
  • TABLE 7.3: GMP Capacities of European CDMOs
  • TABLE 7.4: MHRA-Licensed Manufacturing Facilities
  • TABLE 7.5: Cleanroom Footprint in UK, 2019-2023
  • TABLE 8.1: Examples of Priming Strategies in Animal Models
  • TABLE 8.2: Materials used in Microparticles (MPs) Fabrication
  • TABLE 8.3: Genetic Engineering Method used in MSCs
  • TABLE 8.4: Examples of Bioengineered MSCs as Living Drug Factories
  • TABLE 8.5: Examples of Oncology Indications being Studied using Engineered MSCs
  • TABLE 8.6: Effects of Engineered MSCs in Neurological Indications
  • TABLE 9.1: Select MSC-Based Clinical Trials for Autoimmune Diseases
  • TABLE 9.2: Select MSC-Based Clinical Trials for Cardiovascular Diseases
  • TABLE 9.3: Select MSC-Based Clinical Studies for Neurological Diseases
  • TABLE 9.4: Select MSC-Based Studies for Musculoskeletal Disorders
  • TABLE 9.5: Select Ongoing Studies using MSCs for GvHD
  • TABLE 9.6: Studies using MSCs in Crohn's Diseases
  • TABLE 9.7: Select Studies using MSCs in Type 1 Diabetes
  • TABLE 9.8: Select Studies using MSCs in Systemic Lupus Erythematosus (SLE)
  • TABLE 9.9: Select Studies using MSCs in Parkinson's Disease
  • TABLE 9.10: Select Ongoing Studies using MSCs in Alzheimer's Disease
  • TABLE 9.11: Select Ongoing Studies using MSCs in Kidney Failure
  • TABLE 9.12: Select Studies using MSCs in Spinal Cord Injury
  • TABLE 9.13: Select Studies using MSCs for Wound Healing
  • TABLE 11.1: Currently Available MSC Therapies
  • TABLE 11.2: Queencell - Product Information
  • TABLE 11.3: Cellgram AMI - Product Information
  • TABLE 11.4: Cupistem - Product Information
  • TABLE 11.5: Cartistem - Product Information
  • TABLE 11.6: NeuroNataR - Product Information
  • TABLE 11.7: Holoclar - Product Information
  • TABLE 11.8: Prochymal/Ryoncil (Remestemcel-L) - Product Information
  • TABLE 11.9: Temcell HS - Product Information
  • TABLE 11.10: Stempeucel - Product Information
  • TABLE 11.12: MesestroCell - Product Information
  • TABLE 11.13: Stemirac - Product Information
  • TABLE 11.14: Currently Marketed Biomaterial-Based MSCs & MSC Progenitors
  • TABLE 11.15: Osteocel - Product Information
  • TABLE 11.16: AlloStem - Product Information
  • TABLE 11.17: Grafix - Product Information
  • TABLE 11.18: Cellentra VCBM - Product Information
  • TABLE 11.19: Trinity ELITE - Product Information
  • TABLE 11.20: Map3 - Product Information
  • TABLE 11.21: Bio4 - Product Information
  • TABLE 11.22: Trinity Evolution - Product Information
  • TABLE 11.23: Carticel - Product Information
  • TABLE 11.24: Chondron - Product Information
  • TABLE 11.25: DeNovo NT - Product Information
  • TABLE 11.26: Ossron - Product Information
  • TABLE 11.27: JACC - Product Information
  • TABLE 11.28: MACI - Product Information
  • TABLE 11.29: Ortho-ACI - Product Information
  • TABLE 11.30: Ossgrow - Product Information
  • TABLE 11.31: Cartigrow - Product Information
  • TABLE 11.32: Commercially Available Skincare Cosmetics with MSC-Derived Exosomes
  • TABLE 12.1: Global Market for MSC-Based Therapeutics, 2024-2031
  • TABLE 12.2: Global Market for Mesenchymal Stem Cells (MSCs),2024-2031
  • TABLE 13.1: Aegle's Product Pipeline
  • TABLE 13.2: Ambulero's Product Pipeline
  • TABLE 13.3: Amniotics' Product Pipeline
  • TABLE 13.4: Baylx's Product Pipeline
  • TABLE 13.5: BioCardia's Product Pipeline
  • TABLE 13.6: Bonus Biogroup's Product Pipeline
  • TABLE 13.7: BrainStorm's Clinical Trials
  • TABLE 13.8: CELLeBRAIN's Product Pipeline
  • TABLE 13.9: CellProthera's Preclinical and Clinical Pipeline
  • TABLE 13.10: Celltex's Clinical Trials
  • TABLE 13.11: Corestem's Product Pipeline
  • TABLE 13.12: Creative Medical's Preclinical and Clinical Pipeline
  • TABLE 13.13: Regulatory Proteins found in ExoFlo
  • TABLE 13.14: Hopes Clinical Trial Pipeline using HB-adMSC
  • TABLE 13.15: Kangstem's Sponsor Initiated Clinical Trials
  • TABLE 13.16: Longeveron's Clinical Pipeline
  • TABLE 13.17: NextCell's Products in Pipeline
  • TABLE 13.18: Novadip's Product Pipeline
  • TABLE 13.19: RHEACELL's Products in Pipeline
  • TABLE 13.20: San Bio's Product Pipeline
  • TABLE 13.21: Stemedica's Product Pipeline
  • TABLE 13.22: Stempeutics' Product Development Status
  • TABLE 13.23: Xintela's Product Pipeline